Arkolith/Insider Trading/INZY/Form 4

Hopfner Robert Lorne

DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed May 15, 2023
Net Buying
Open-Market Buys
$2.8M
Open-Market Sells
$0
Net Open-Market Flow
$2.8M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 12, 2023Buy(P)229K$6.25$1.4M3.7M
May 11, 2023Buy(P)219K$6.48$1.4M3.4M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-029521) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML